• 1
    Ikehara S. Bone marrow transplantation: a new strategy for intractable disease. Drugs Today 2002; 38:10311.
  • 2
    Ikehara S, Ohtsuki H, Good RA et al. Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation. Proc Natl Acad Sci USA 1985; 22:77437.
  • 3
    Yasumizu R, Sugiura K, Iwai H et al. Treatment of type 1 diabetes mellitus in non-obese diabetic mice by transplantation of allogeneic bone marrow and pancreatic tissue. Proc Natl Acad Sci USA 1987; 84:65557.
  • 4
    Than S, Ishida H, Inaba M et al. Bone marrow transplantation as a strategy for treatment of non-insulin-dependent diabetes mellitus in KK-Ay mice. J Exp Med 1992; 176:12338.
  • 5
    Ishida T, Inaba M, Hisha H et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-lpr/lpr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol 1994; 152:311927.
  • 6
    Nakagawa T, Nagata N, Hosaka N, Ogawa R, Nakamura K, Ikehara S. Prevention of autoimmune inflammatory polyarthritis in male New Zealand black/KN mice by transplantation of bone marrow cells plus bone (stromal cells). Arthritis Rheum 1993; 36:2638.
  • 7
    Hosaka N, Nose M, Kyogoku M et al. Thymus transplantation, a critical factor for correction of autoimmune disease in aging MRL/+ mice. Proc Natl Acad Sci USA 1996; 93:855862.
  • 8
    Nishimura M, Toki J, Sugiura K et al. Focal segmental glomerular sclerosis, a type of intractable chronic glomerulonephritis, is a stem cell disorder. J Exp Med 1994; 179:10538.
  • 9
    Spangrude GI, Uchida N, Weissman IL. Overcoming the allogenic barriers. In: AtkinsonK, FibbeWE, eds. Clinical bone marrow and blood stem cell transplantation, 3rd edn. Cambridge, UK: Cambridge University Press, 2004:289.
  • 10
    Chao NJ. Graft-versus-host disease: the viewpoint from the donor T cell. Biol Blood Marrow Transplant 1997; 3:110.
  • 11
    O'Reilly RJ, Keever C, Kernan NA et al. HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc 1987; 19 (Suppl.):5560.
  • 12
    Klingemann HG, Storb R, Fefer A et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986; 67:7706.
  • 13
    Weiner RS, Bortin MM, Gale RP. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med 1986; 104:16875.
  • 14
    Ringdén O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40:3944.
  • 15
    Kushida T, Inaba M, Takeuchi K, Sugiura K, Ogawa R, Ikehara Y. Treatment of intractable autoimmune disease in MRL/lpr mice using a new strategy for allogeneic bone marrow cells transplantation. Blood 2000; 95:18628.
  • 16
    Kushida T, Inaba M, Hisha H et al. Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood 2001; 97:329239.
  • 17
    Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:3147.
  • 18
    Andrews BS, Eisenberg RA, Theofilopoulos AN et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978; 148:1198215.
  • 19
    Ikehara S, Yasumizu R, Inaba M et al. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 1989; 86:330610.
  • 20
    Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc Natl Acad Sci USA 1998; 94:57505.
  • 21
    Holzelova E, Vonarbourg C, Stolzenberg MC et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 2004; 351:140918.
  • 22
    Markert ML, Boeck A, Hale LP, Kloster AL, McLaughlin TM. Transplantation of thymus tissue in complete DiGeorge syndrome. N Engl J Med 1999; 341:11809.
  • 23
    Markert ML, Hicks CB, Bartlett JA, Harmon JL. Hale effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res Hum Retroviruses 2000; 16:40313.
  • 24
    Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Meth 1995; 184:3951.
  • 25
    Tadokoro Y. Purification of hematopoietic stem cells and clone sorting. In: NakauchiH, ed. Flowcytometry jiyujizai. Tokyo, Japan: Shujyunsha, 1999:1339.
  • 26
    Miyashima S, Nagata N, Nakagawa T, Hosaka N, Takeuchi K, Ikehara S. Prevention of lpr-graft-versus-host disease and transfer of autoimmune disease in normal C57BL/6 mice by transplantation of bone marrow cells plus bones (stroma cells) from MRL/lpr mice. J Immunol 1996; 156:7984.
  • 27
    Reisner Y, Martelli MF. Transplantation tolerance induced by ‘mega dose’ CD34+ cell transplants. Exp Hematol 2000; 28:11927.
  • 28
    Moore NC, Anderson G, Smith CA, Owen JJ, Jenkinson EJ. Analysis of cytokine gene expression in subpopulations of freshly isolated thymocytes and thymic stromal cells using semiquantitative polymerase chain reaction. Eur J Immunol 1993; 23:9227.
  • 29
    Ford MS, Young KJ, Zhang Z, Ohashi PS, Zhang L. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J Exp Med 2002; 196:2617.
  • 30
    Pati AR, Godder K, Lamb L, Gee A, Henslee-Downey PJ. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 1995; 15:97981.
  • 31
    Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 2002; 11:26576.
  • 32
    Watanabe D, Suda T, Hashimoto H, Nagata S. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J 1995; 14:128.
  • 33
    Allen RD, Marshall JD, Roths JB, Sidman CL. Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules. J Exp Med 1990; 172:136775.
  • 34
    Adachi M, Suematsu S, Suda T et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 1996; 93:21316.
  • 35
    Miyawaki T, Uehara T, Nibu R et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 149:37538.
  • 36
    Hosaka N, Oyaizu N, Kaplan MH, Yagita H, Pahwa S. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. J Infect Dis 1998; 178:10309.
  • 37
    Gabor MJ, Scollay R, Godfrey DI. Thymic T cell export is not influenced by the peripheral T cell pool. Eur J Immunol 1997; 27:298693.